News
HAE
91.06
+0.51%
0.46
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
NASDAQ · 10h ago
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
NASDAQ · 1d ago
Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View
NASDAQ · 1d ago
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
NASDAQ · 2d ago
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
NASDAQ · 2d ago
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
NASDAQ · 2d ago
HAE vs. BSX: Which Stock Is the Better Value Option?
NASDAQ · 3d ago
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings
NASDAQ · 3d ago
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
NASDAQ · 3d ago
Elanco (ELAN) Stock Declines After Sale of Aqua Business
NASDAQ · 4d ago
Weekly Report: what happened at HAE last week (0715-0719)?
Weekly Report · 4d ago
Globus Medical (GMED) Global Sales, Innovation Aid Growth
NASDAQ · 07/19 14:37
Patterson (PDCO) Expands AI Solutions in Canada via Alliance
NASDAQ · 07/19 14:34
Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why
NASDAQ · 07/18 17:14
Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
NASDAQ · 07/18 17:14
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
NASDAQ · 07/18 15:49
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
NASDAQ · 07/18 14:32
Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D
NASDAQ · 07/18 13:34
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Haemonetics Corporation (NYSE:HAE) is estimated to be 46% undervalued. The projected fair value for Haemonetics is US$167 based on 2 Stage Free Cash Flow to Equity. Analyst price target for HAE is 32% below our fair value estimate. We will use a discounted cash flow model to estimate the stock's intrinsic value.
Simply Wall St · 07/18 13:22
Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note
NASDAQ · 07/18 12:53
More
Webull provides a variety of real-time HAE stock news. You can receive the latest news about Haemonetics Corp Mass through multiple platforms. This information may help you make smarter investment decisions.
About HAE
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Company’s Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.